The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death
Open accessAbstract
Tumor development principally occurs following the accumulation of genetic and epigenetic alterations in tumor cells. These changes pave the way for the transformation of chemosensitive cells to chemoresistant ones by influencing the uptake, metabolism, or export of drugs at the cellular level. Numerous reports have revealed the complexity of tumors and their microenvironment with tumor cells located within a heterogeneous population of stromal cells. These stromal cells (fibroblasts, endothelial or mesothelial cells, adipocytes or adipose tissue-derived stromal cells, immune cells and bone marrow-derived stem cells) could be involved in the chemoresistance that is acquired by tumor cells via several mechanisms: (i) cell–cell and cell–matrix interactions influencing the cancer cell sensitivity to apoptosis; (ii) local release of soluble factors promoting survival and tumor growth (crosstalk between stromal and tumor cells); (iii) direct cell-cell interactions with tumor cells (crosstalk or oncologic trogocytosis); (iv) generation of specific niches within the tumor microenvironment that facilitate the acquisition of drug resistance; or (v) conversion of the cancer cells to cancer-initiating cells or cancer stem cells. This review will focus on the implication of each member of the heterogeneous population of stromal cells in conferring resistance to cytotoxins and physiological mediators of cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kong, W., He, L., Coppola, M., Guo, J., Esposito, N. N., Coppola, D., & Cheng, J. Q. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.101055 · Cited by 377
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“The key molecule acting during hypoxia is hypoxia-inducible transcription factor 1 (HIF-1) which transactivates hundreds of genes including angiogenic and autocrine growth factors and receptors, glycolytic enzymes and extracellular proteases [63].”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Not only does this allow a better delivery of chemotherapy and increase the sensitivity to radiotherapy but it also decreases tumor cell extravasation and migration in the blood circulation by reestablishing the endothelial cell barrier [55,59].”
BackgroundMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 1×
“cell-cell interactions with tumor cells (crosstalk or oncologic trogocytosis) [7]; iv) the generation of specific niches within the tumor microenvironment comprising subpopulations of tumor cells that may afford a survival advantage following initial drug exposure and/or enhance hypoxia leading to the up-regulation of…”
BackgroundInfluentialEltzschig, H. K., & Carmeliet, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0910283 · Cited by 2,061
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Holmgren, L., O'Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,878
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
DeNardo, D. G., Barreto, J. B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., & Coussens, L. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.018 · Cited by 1,353
Carmeliet, P., Lampugnani, M.-G., Moons, L., Breviario, F., Compernolle, V., Bono, F., Balconi, G., Spagnuolo, R., Oosthuyse, B., Dewerchin, M., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81010-7 · Cited by 1,283
Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,200
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189
Angiostatin induces and sustains dormancy of human primary tumors in mice
O'Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,184
Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.-H., Pagès, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2907 · Cited by 1,146
Endothelial-pericyte interactions in angiogenesis
Gerhardt, H., & Betsholtz, C. (2003) · Cell and Tissue Research · doi:10.1007/s00441-003-0745-x · Cited by 1,057
Liu, Y., Cox, S. R., Morita, T., & Kourembanas, S. (1995) · Circulation Research · doi:10.1161/01.res.77.3.638 · Cited by 1,040
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · cited 1×
“They also showed that combining anti-VEGF treatment and a monoclonal antibody targeting myeloid cells allowed a better growth inhibition than anti-VEGF alone in refractory tumors [93].”
BackgroundAnti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 779
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758
Cancer associated fibroblasts (CAFs) in tumor microenvironment
Xing, F. (2010) · Frontiers in Bioscience · doi:10.2741/3613 · Cited by 682
Lee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 677
Nör, J. E., Christensen, J., Mooney, D. J., & Polverini, P. J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65284-4 · Cited by 641
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633
TH17 cells in tumour immunity and immunotherapy
Zou, W., & Restifo, N. P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2742 · Cited by 624
Rohwer, N., & Cramer, T. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.03.001 · Cited by 608
Park, J. E., Lenter, M. C., Zimmermann, R. N., Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36505 · Cited by 586
Fujio, Y., & Walsh, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16349 · Cited by 553
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development · doi:10.1101/gad.180331.111 · Cited by 541 · cited 1×
“Indeed, the combination of anti-cathepsin with taxol treatment enhances the anti-tumor efficacy, the late-stage survival and decreases the metastatic burden compared to taxol alone in a breast cancer mouse model [97].”
BackgroundImmune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468
Survivin, a cancer target with an emerging role in normal adult tissues
Fukuda, S., & Pelus, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0375 · Cited by 465
Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T., Cho, H.-I., Antonia, S., Altiok, S., Celis, E., & Gabrilovich, D. I. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40269 · Cited by 460
The tumor microenvironment is a dominant force in multidrug resistance
Correia, A. L., & Bissell, M. J. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.006 · Cited by 443
Biswas, S. K., Sica, A., & Lewis, C. E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2011 · Cited by 435
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
Dias, S., Hattori, K., Zhu, Z., Heissig, B., Choy, M., Lane, W., Wu, Y., Chadburn, A., Hyjek, E., Gill, M., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8978 · Cited by 434
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
Tran, J., Master, Z., Yu, J. L., Rak, J., Dumont, D. J., & Kerbel, R. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072586399 · Cited by 434
Halama, N., Michel, S., Kloor, M., Zoernig, I., Benner, A., Spille, A., Pommerencke, T., von Knebel, D. M., Folprecht, G., Luber, B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0268 · Cited by 420
Ringe, J., Strassburg, S., Neumann, K., Endres, M., Notter, M., Burmester, G., Kaps, C., & Sittinger, M. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21172 · Cited by 371
Iyengar, P., Combs, T. P., Shah, S. J., Gouon-Evans, V., Pollard, J. W., Albanese, C., Flanagan, L., Tenniswood, M. P., Guha, C., Lisanti, M. P., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206737 · Cited by 363
Role of microRNAs in drug-resistant ovarian cancer cells
Sorrentino, A., Liu, C.-G., Addario, A., Peschle, C., Scambia, G., & Ferlini, C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.017 · Cited by 354
Control of Apoptosis during Angiogenesis by Survivin Expression in Endothelial Cells
O'Connor, D. S., Schechner, J. S., Adida, C., Mesri, M., Rothermel, A. L., Li, F., Nath, A. K., Pober, J. S., & Altieri, D. C. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64742-6 · Cited by 341
Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy
Ma, Y., Aymeric, L., Locher, C., Mattarollo, S. R., Delahaye, N. F., Pereira, P., Boucontet, L., Apetoh, L., Ghiringhelli, F., Casares, N., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100269 · Cited by 337
Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0753 · Cited by 333
FUKS, Z. Y., Persaud, R. S., Alfieri, A. A., McLoughlin, M., Ehleiter, D., Schwartz, J. L., Seddon, A. P., Cordon‐Cardo, C., & Haimovitz‐Friedman, A. (1994) · PubMed · Cited by 331
The multifaceted role of periostin in tumorigenesis
Ruan, K., Bao, S., & Ouyang, G. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0013-7 · Cited by 326
Franco, M., Roswall, P., Cortez, E., Hanahan, D., & Pietras, K. (2011) · Blood · doi:10.1182/blood-2011-01-331694 · Cited by 310
Roodhart, J. M. L., Daenen, L. G. M., Stigter, E. C. A., Prins, H.-J., Gerrits, J., Houthuijzen, J. M., Gerritsen, M. G., Schipper, H. S., Backer, M. J. G., van Amersfoort, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.010 · Cited by 305
Ma, J., Dong, C., & Ji, C. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.18 · Cited by 303
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?
De Bock, K., Mazzone, M., & Carmeliet, P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.83 · Cited by 293
Regulation of Endothelial Cell Survival and Apoptosis During Angiogenesis
Chavakis, E., & Dimmeler, S. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000017728.55907.a9 · Cited by 285
Circulating MiR-125b as a Marker Predicting Chemoresistance in Breast Cancer
Wang, H., Tan, G., Dong, L., Cheng, L., Li, K., Wang, Z., & Luo, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034210 · Cited by 275
High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma
Hebert, C., Norris, K., Scheper, M. A., Nikitakis, N., & Sauk, J. J. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-5 · Cited by 274
Dias, S., Shmelkov, S. V., Lam, G., & Rafii, S. (2002) · Blood · doi:10.1182/blood.v99.7.2532 · Cited by 260
Hamano, R., Miyata, H., Yamasaki, M., Kurokawa, Y., Hara, J., Moon, J. H., Nakajima, K., Takiguchi, S., Fujiwara, Y., Mori, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2532 · Cited by 243
Bourguignon, L. Y. W., Earle, C., Wong, G., Spevak, C. C., & Krueger, K. (2012) · Oncogene · doi:10.1038/onc.2011.222 · Cited by 239
Antiangiogenic therapy and tumor progression
Blagosklonny, M. V. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00336-2 · Cited by 235
Hypoxia and energetic tumour metabolism
Brahimi-Horn, M. C., Bellot, G., & Pouysségur, J. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.006 · Cited by 226
Resistance to adriamycin in multicellular spheroids
Sutherland, R. M., Eddy, H. A., Bareham, B., Reich, K., & Vanantwerp, D. (1979) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(79)90643-6 · Cited by 225
Johansson, A., Rudolfsson, S., Hammarsten, P., Halin, S., Pietras, K., Jones, J., Stattin, P., Egevad, L., Granfors, T., Wikström, P., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100070 · Cited by 216
Jin, L., Tabe, Y., Konoplev, S., Xu, Y., Leysath, C. E., Lu, H., Kimura, S., Ohsaka, A., Rios, M.-B., Calvert, L., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0042 · Cited by 209
Pidgeon, G. P., Barr, M. P., Harmey, J. H., Foley, D. A., & Bouchier-Hayes, D. J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1876 · Cited by 208
Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis
Mohan, M., Lin, C., Guest, E., & Shilatifard, A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2915 · Cited by 199
Reardon, D. A., Akabani, G., Coleman, R. E., Friedman, A. H., Friedman, H. S., Herndon, J. E., McLendon, R. E., Pegram, C. N., Provenzale, J. M., Quinn, J. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4082 · Cited by 197
Rao, E., Jiang, C., Ji, M., Huang, X., Iqbal, J., Lenz, G., Wright, G., Staudt, L. M., Zhao, Y., McKeithan, T. W., et al. (2012) · Leukemia · doi:10.1038/leu.2011.305 · Cited by 188
The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma
Sirica, A. E. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.222 · Cited by 188
Adipocytes Impair Leukemia Treatment in Mice
Behan, J. W., Yun, J. P., Proektor, M. P., Ehsanipour, E. A., Arutyunyan, A., Moses, A. S., Avramis, V. I., Louie, S. G., Butturini, A., Heisterkamp, N., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0800 · Cited by 183
Karsan, A., Yee, E., Poirier, G. G., Zhou, P., Craig, R. W., & Harlan, J. M. (1997) · Europe PMC (PubMed Central) · Cited by 180
Serebriiskii, I., Castelló-Cros, R., Lamb, A., Golemis, E. A., & Cukierman, E. (2008) · Matrix Biology · doi:10.1016/j.matbio.2008.02.008 · Cited by 176
Out of air is not out of action
Bottaro, D. P., & Liotta, L. A. (2003) · Nature · doi:10.1038/423593a · Cited by 168
Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling in cholangiocarcinoma cells
Fingas, C. D., Bronk, S. F., Werneburg, N. W., Mott, J. L., Guicciardi, M. E., Cazanave, S. C., Mertens, J. C., Sirica, A. E., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.24588 · Cited by 163
VEGF, a prosurvival factor, acts in concert with TGF-β1 to induce endothelial cell apoptosis
Ferrari, G., Pintucci, G., Seghezzi, G., Hyman, K., Galloway, A. C., & Mignatti, P. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605556103 · Cited by 160
Harmey, J. H., & Bouchier‐Hayes, D. M. (2002) · BioEssays · doi:10.1002/bies.10043 · Cited by 155
Liu, H., Zhang, T., Jin, Y., Li, H., Huang, J., Li, X., Wu, B., Huang, X., & Hou, J. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1231-7 · Cited by 146
Stassi, G., Todaro, M., Zerilli, M., Ricci‐Vitiani, L., Liberto, D. D., Patti, M., Florena, A., Gaudio, F. D., Gesù, G. D., & Maria, R. D. (2003) · PubMed · Cited by 144
Cancer-associated adipocytes promotes breast tumor radioresistance
Bochet, L., Meulle, A., Imbert, S., Salles, B., Valet, P., & Muller, C. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.101 · Cited by 140
Biroccio, A., Candiloro, A., Mottolese, M., Sapora, O., Albini, A., Zupi, G., & Bufalo, D. D. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.5.652 · Cited by 139
Hazlehurst, L. A., Enkemann, S. A., Beam, C. A., Argilagos, R. F., Painter, J. S., Shain, K. H., Saporta, S., Boulware, D. C., Moscinski, L. C., Alsina, M., et al. (2003) · PubMed · Cited by 138
Lee, Y. K., Shanafelt, T. D., Bone, N. D., Strege, A. K., Jelinek, D. F., & Kay, N. E. (2005) · Leukemia · doi:10.1038/sj.leu.2403667 · Cited by 125
Hao, M., Zhang, L., An, G., Meng, H., Han, Y.-J., Xie, Z., Xu, Y., Li, C., Yu, Z., Chang, H. H., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.576791 · Cited by 123
Benito, J., Shi, Y., Szymanska, B., Carol, H., Boehm, I., Lu, H., Konoplev, S. N., Fang, W., Zweidler‐McKay, P. A., Campana, D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023108 · Cited by 122
Padera, T. P., Kuo, A. H., Hoshida, T., Liao, S., Shah, J. L., Kozak, K. R., Fukumura, D., & Jain, R. K. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0182 · Cited by 120
The cellular response to hypoxia: tuning the system with microRNAs
Loscalzo, J. (2010) · Journal of Clinical Investigation · doi:10.1172/jci45105 · Cited by 119
Lis, R., Touboul, C., Mirshahi, P., Ali, F., Mathew, S. A., Nolan, D. J., Maleki, M., Abdalla, S. A., Raynaud, C. M., Querleu, D., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25619 · Cited by 117
Two Steps Forward in the Treatment of Colorectal Cancer
Mayer, R. J. (2004) · New England Journal of Medicine · doi:10.1056/nejme048098 · Cited by 116
Oncologic Trogocytosis of an Original Stromal Cells Induces Chemoresistance of Ovarian Tumours
Rafii, A., Mirshahi, P., Poupot, M., Faussat, A., Simon, A., Ducros, E., Mery-Lamarche, E., Couderc, B. C., Lis, R., Capdet, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003894 · Cited by 116
Self-citationAdult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence
Rhodes, L. V., Muir, S. E., Elliott, S. G., Guillot, L. M., Antoon, J. W., Penfornis, P., Tilghman, S. L., Salvo, V. A., Fonseca, J. P., Lacey, M. R., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0458-2 · Cited by 110
der Most, R. G. V., Currie, A. J., Cleaver, A. L., Salmons, J., Nowak, A. K., Mahendran, S., Larma, I., Prosser, A., Robinson, B. W. S., Smyth, M. J., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006982 · Cited by 109
Stoeck, A., Gast, D., Sanderson, M. P., Issa, Y., Gutwein, P., & Altevogt, P. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.08.038 · Cited by 107
Teng, I.-W., Hou, P., Lee, K., Chu, P., Yeh, K., Jin, V. X., Tseng, M., Tsai, S., Chang, Y., Wu, C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3418 · Cited by 106
Shain, K. H., Landowski, T. H., & Dalton, W. S. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200011000-00008 · Cited by 101
Increased Survivin Expression Confers Chemoresistance to Tumor-Associated Endothelial Cells
Virrey, J. J., Guan, S., Li, W., Schönthal, A. H., Chen, T. C., & Hofman, F. M. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.071079 · Cited by 96
Pittoni, P., Piconese, S., Tripodo, C., & Colombo, M. P. (2010) · Oncogene · doi:10.1038/onc.2010.494 · Cited by 96
Vascular endothelial growth factor receptor‐1 in human cancer
Schwartz, J. D., Rowinsky, E. K., Youssoufian, H., Pytowski, B., & Wu, Y. L. (2010) · Cancer · doi:10.1002/cncr.24789 · Cited by 95
Multiple Myeloma Bone Marrow Niche
Basak, G. W., Srivastava, A., Malhotra, R., & Carrier, E. (2009) · Current Pharmaceutical Biotechnology · doi:10.2174/138920109787847493 · Cited by 90
Halama, N., Michel, S., Kloor, M., Zoernig, I., Pommerencke, T., Doeberitz, M. V. K., Schirmacher, P., Weitz, J., Grabe, N., & Jäger, D. (2009) · PubMed · Cited by 84
Tu, S. P., Cui, J. T., Liston, P., Jiang, X. H., Xu, R., Lin, M. C. M., Zhu, Y. B., Zou, B., Ng, S. S., Jiang, S. H., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.058 · Cited by 82
Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis
Pasquet, M., Golzio, M., Mery, E., Rafii, A., Benabbou, N., Mirshahi, P., Hennebelle, I., Bourin, P., Allal, B., Teissie, J., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.24886 · Cited by 82
Self-citationZhang, L., Hannay, J. A. F., Liu, J., Das, P. K., Zhan, M., Nguyen, T. P. T., Hicklin, D. J., Yu, D., Pollock, R. E., & Lev, D. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1217 · Cited by 80
Müerköster, S. S., Werbing, V., Koch, D., Sipos, B., Ammerpohl, O., Kalthoff, H., Tsao, M., Fölsch, U. R., & Schäfer, H. (2008) · International Journal of Cancer · doi:10.1002/ijc.23703 · Cited by 73
Samuel, S., Fan, F., Dang, L. H., Xia, L., Gaur, P., & Ellis, L. M. (2010) · Oncogene · doi:10.1038/onc.2010.496 · Cited by 72
Zhao, R., Wu, J., Jia, W., Gong, C., Yu, F., Ren, Z., Chen, K., He, J., & Su, F. (2011) · Onkologie · doi:10.1159/000334552 · Cited by 71
The Role of Initiating and Promoting Factors in the Pathogenesis of Tumours of the Thyroid
Hall, W. H. (1948) · British Journal of Cancer · doi:10.1038/bjc.1948.32 · Cited by 68
Xu, T., Chen, J., Lu, Y., & Wolff, J. E. A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-252 · Cited by 64
Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects
Ding, Z., & Zhou, G. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/890178 · Cited by 63
Glioblastoma cells block radiation-induced programmed cell death of endothelial cells
Brown, C. K., Khodarev, N. N., Yu, J. J., Moo‐Young, T. A., Labay, E., Darga, T. E., Posner, M. C., Weichselbaum, R. R., & Mauceri, H. J. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.03.099 · Cited by 62
Yang, F., Tang, X., Riquelme, E. M., Behrens, C., Nilsson, M. B., Giri, U. P., Varella‐Garcia, M., Byers, L. A., Lin, H. Y., Wang, J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2614 · Cited by 61
Disabling Abl—Perspectives on Abl kinase regulation and cancer therapeutics
Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00022-3 · Cited by 61
BMSC enhance the survival of paclitaxel treated squamous cell carcinoma cells in vitro
Scherzed, A., Hackenberg, S., Froelich, K., Kessler, M. T., Koehler, C. J., Hagen, R., Radeloff, A., Friehs, G., & Kleinsasser, N. H. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.3.14179 · Cited by 61
Margolin, D. A., Silinsky, J., Grimes, C., Spencer, N. D., Aycock, M., Green, H., Cordova, J., Davis, N. K., Driscoll, T., & Li, L. (2011) · Neoplasia · doi:10.1593/neo.11324 · Cited by 60
Angst, E., Reber, H. A., Hines, O. J., & Eibl, G. (2008) · Surgery · doi:10.1016/j.surg.2008.03.024 · Cited by 59
The Dark Side of Mast Cell–Targeted Therapy in Prostate Cancer
Pittoni, P., & Colombo, M. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3110 · Cited by 59
Anai, S., Goodison, S., Shiverick, K. T., Hirao, Y., Brown, B. D., & Rosser, C. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0367 · Cited by 57
Fonsato, V., Buttiglieri, S., Deregibus, M. C., Puntorieri, V., Bussolati, B., & Camussi, G. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050776 · Cited by 55
Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages
Castells, M., Thibault, B., Mery-Lamarche, E., Golzio, M., Pasquet, M., Hennebelle, I., Bourin, P., Mirshahi, M., Delord, J. P., Querleu, D., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.07.020 · Cited by 49
Self-citationThomas, X., Anglaret, B., Magaud, J., Epstein, J., & Archimbaud, E. (1998) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199809059251 · Cited by 43
Xu, Y., Tabe, Y., Jin, L., Watt, J. C., McQueen, T. J., Ohsaka, A., Andreeff, M., & Konopleva, M. Y. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07130.x · Cited by 39
Wang, L., Chen, L., Benincosa, J., Fortney, J. E., & Gibson, L. F. (2005) · Leukemia · doi:10.1038/sj.leu.2403643 · Cited by 35
Michaelis, M., Klassert, D., Barth, S., Suhan, T. O., Breitling, R., Mayer, B., Hinsch, N., Doerr, H. W., Činátl, J., & Cinatl, J. J. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-80 · Cited by 35
Childhood acute leukemia with t(11;19) (q23;p13).
Hudson, M. M., Raimondi, S. C., Behm, F. G., & Pui, C. (1991) · PubMed · Cited by 25
Cited by
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
Sever, R., & Brugge, J. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006098 · Cited by 989
Carcinoma-associated fibroblasts: orchestrating the composition of malignancy
Gascard, P., & Tlsty, T. D. (2016) · Genes & Development · doi:10.1101/gad.279737.116 · Cited by 732
Mechanisms and insights into drug resistance in cancer
Zahreddine, H., & Borden, K. L. B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00028 · Cited by 660
Metadata
- Authors
- Castells, M., Thibault, B., Delord, J.-P., & Couderc, B.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2012-07-30
- Volume
- 13
- Issue
- 8
- Pages
- 9545-9571
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2076306819
- Cited by
- 285
- References
- 133
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.